Diligence memo · auto-generated · as of July 2, 2026
Delee Corp
Delee Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Delee Corp operates in Biotechnology, based in LAREDO, N.L., Mexico. Blood testing device for early diagnosis of cancer and treatment…
Sub-sector tags: Diagnostics, Medical Devices, medical-devices.
Capital & rounds (filed)filed
Delee Corp has raised $1.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2017-01-11.
Most recent recorded round closed around 2017-01-11.
Valuation (modeled)modeled
Provath models Delee Corp at approximately $52M (range $846K–$409M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 9.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 20% of Biotechnology peers (4293 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.